Výsledky vyhledávání

Akademický článek

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]

Autor: Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris III HA, Zamboni WC

Publikováno v: International Journal of Nanomedicine, Vol Volume 14, Pp 5751-5752 (2019)

Wu H, Infante JR, Keedy VL, et al. Int J Nanomedicine. 2015:10;1201—1209 On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication. Read the original article

Externí odkaz: https://doaj.org/article/f7e040c8333d42af9a814346b023d546

Zobrazit plný text záznamu

Akademický článek

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors

Autor: Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris III HA, Zamboni WC

Publikováno v: International Journal of Nanomedicine, Vol 2015, Iss default, Pp 1201-1209 (2015)

Huali Wu,1 Jeffrey R Infante,2 Vicki L Keedy,3 Suzanne F Jones,2 Emily Chan,3 Johanna C Bendell,2 Wooin Lee,4 Whitney P Kirschbrown,1 Beth A Zamboni,5 Satoshi Ikeda,6 Hiroshi Kodaira,6 Mace L Rothenberg,3 Howard A Burris III,2 William C Zamboni1,7–

Externí odkaz: https://doaj.org/article/1a54bb16f81f43a787b71066de2de6f5

Zobrazit plný text záznamu

A phase i dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

Autor: Munster, Pamela, Bergsland, Emily, Kelley, Robin Kate, Bendell, JC, Kelley, RK, Shih, KC, Grabowsky, JA, Jones, S, Martin, T, Infante, JR, Mischel, PS, Matsutani, T

Publikováno v: Munster, Pamela; Bergsland, Emily; Kelley, Robin Kate; Bendell, JC; Kelley, RK; Shih, KC; et al.(2015). A phase i dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/9sq7h6jn

© 2015 American Cancer Society.BACKGROUND The mammalian target of rapamycin (mTOR) pathway is essential for tumor development, yet mTOR inhibitors have yielded modest results. This phase 1 study investigated the mTORC1/mTORC2 inhibitor CC-223 in pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::fb775ecc20d69b0d8a5e91c37bed7555
http://www.escholarship.org/uc/item/9sq7h6jn

Zobrazit plný text záznamu

Vertebral hemangioma: 'Cold' vertebrae on bone scintigraphy and fluordeoxy-glucose positron emission tomography–computed tomography

Autor: Domínguez, ML, Rayo, JI, Serrano, J, Sánchez, R, Infante, JR, García, L, Durán, C

Publikováno v: Indian Journal of Nuclear Medicine : IJNM : The Official Journal of the Society of Nuclear Medicine, India

Bone hemangiomas are benign and infrequent lesions. At Tc-99m bone scintigraphy they show variable degrees of radiotracer uptake and even absence of it. At fluordeoxy-glucose (FDG) Positron Emission Tomography-Computed Tomography (PET/CT), hemangioma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9ba627b7643da6da68b8d559c0833f60
http://europepmc.org/articles/PMC3180726

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání